ClinicalTrials.gg
CompletedNCT05106400Updated Nov 3, 2021

Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches

A Phase 1 interventional study of ZTlido (Lidocaine Topical System) 1.8% and Salonpas (Lidocaine Patch 4%) in Healthy, sponsored by Scilex Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-11-03.

Sponsored by Scilex Pharmaceuticals, Inc. · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jul 2021, 5 years 3 months ago, and no results have been posted to the registry.
  • Registered 3 months after the study started (first participant enrolled Jul 2021, registered Oct 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study is designed to evaluate and compare the clinical adhesion performance of the ZTlido (Lidocaine Topical System) 1.8% of Scilex Pharmaceuticals Inc. (Reference) versus Salonpas (Lidocaine Patch 4%), Aspercreme (Lidocaine Patch 4%) and IcyHot (Lidocaine 4% + Menthol 1% Patch), on the Mid to upper back while being worn for 12 hours in healthy adult human subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Scilex Pharmaceuticals, Inc. is the lead sponsor of 13 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy, male and female subjects aged 18 years and older with a (BMI) range 18.0-32.49 kg/m2 inclusive (according to the formula of BMI = weight (kg) / [height (m)2]).
  • Subjects who have no evidence of underlying disease during screening and check-in and whose screening is performed within 28 days of check-in.
  • Subjects whose screening laboratory values are within normal limits or considered by the physician or Principal Investigator to be of no clinical significance.
  • Absence of disease markers of 1 \& 2, \& C virus.
  • Generally healthy as documented by the medical history, physical examination (including but may not be limited to an evaluation of the cardiovascular, gastrointestinal, respiratory, musculoskeletal and central nervous systems) and vital sign assessments.
  • Generally healthy as documented by 12-lead (ECG), and clinical laboratory assessments.
  • Any abnormalities/deviations from the acceptable range of medical history, clinical laboratory values, ECG and vitals, that might be considered by the study physician or investigator will be evaluated as individual cases.
  • Subjects able to comply with study procedures, in the opinion of the Principal Investigator.
  • Willing to give written consent and adhere to all the requirements of this protocol.
  • Female subjects of ;
  • Non-pregnant and non-lactating females practicing medically acceptable forms of and willing to continue during the study.
  • Female- Age > 45 years and Amenorrhea for at least 1 year; or Bilateral Oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months; or Total hysterectomy and an absence of bleeding for at least 3 months.
  • Male volunteers must practice protected sex throughout the study.

Exclusion criteria

Exclusion Criteria:

  • Evidence of allergy or known to lidocaine, local anesthetics of the amide type e.g., bupivacaine, etidocaine, mepivacaine and prilocaine or to any of the components of formulation.Any major illness in the last three months or any significant chronic medical illness.
  • Subjects with history of addiction, abuse, and misuse of any drug - as per physician discretion.
  • Subjects with history of mental illness as per physician discretion.
  • Presence or history of a disorder involving the cardiovascular, respiratory, renal, hepatic, dermatologic, musculoskeletal, gastrointestinal, immunologic, hematologic, endocrine or neurologic system(s) or psychiatric disease (as determined by the Medical Investigator).
  • Participation in any clinical trial within 30 days prior to product application.
  • Subjects with inflamed or injured skin, such as active herpes zoster lesions, atopic dermatitis or wounds where the product will be placed.
  • Presence of any skin condition such as scratches, cuts, scars, abrasions, excessive hair, tattoos, moles, recently shaved skin, uneven skin texture, open sores, irritated (redness, rash, or blisters, etc.) or excessively oily skin at the application areas that may affect the application of the study product.
  • Use of make-up, creams, lotions, powders, or other topical products to the skin area where the product will be placed, within 48 hours prior to product application.
  • Use of antihistamines at product application site within 72 hours prior to product application.
  • Using antiarrhythmic drugs (such as tocainide and mexiletine) and local anesthetics within 14 days prior to product application.
  • Radiation therapy within 3 weeks prior to product application
  • History of significant dermatologic cancers (e.g., melanoma, squamous cell carcinoma etc.) except basal cell carcinomas that were superficial and did not involve the investigative sites.
  • Use of nicotine containing products (including e-cigarettes, patches, gum, chewing tobacco, cigars, etc.) within 30 days prior to patch application.
  • Positive results for drugs of abuse and alcohol breath analysis prior to product application.
  • Female subjects:
  • Demonstrating a positive pregnancy screen
  • Who are currently breastfeeding
  • Use of hormone replacement therapy within three months prior to product application.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Other
    ZTlido (Lidocaine Topical System) 1.8%

    Drug: ZTlido (Lidocaine Topical System) 1.8%

  • Other
    Salonpas (Lidocaine Patch 4%)

    Drug: Salonpas (Lidocaine Patch 4%)

  • Other
    Aspercreme (Lidocaine Patch 4%)

    Drug: Aspercreme (Lidocaine Patch 4%)

  • Other
    IcyHot (Lidocaine 4% + Menthol 1% Patch)

    Drug: IcyHot (Lidocaine 4% + Menthol 1% Patch)

Interventions

  • 1 ZTlido (Lidocaine Topical System) 1.8% is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours

  • 1 Salonpas (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours

  • 1 Aspercreme (Lidocaine Patch 4%) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours

  • DrugIcyHot (Lidocaine 4% + Menthol 1% Patch)

    Drug page: Lidocaine

    1 IcyHot (Lidocaine 4% + Menthol 1% Patch) is applied predetermined area on the right or left side of the mid to upper back and worn for 12 hours

06

What researchers measure

Primary outcomes

  1. Change in Percent adhesion

    The adhesion performance (i.e., degree of lifting or detachment) is assessed by clinicians at each time point. The adhesion of Test Products 1, 2, and 3 (each over-the-counter external analgesic lidocaine-containing patch) are compared to the adhesion performance observed for the Reference Product.

    Time frame: 0, 3, 6, 8, 10, and 12 hours

Secondary outcomes

  1. Adverse events

    The number of adverse events observed in each treatment will be used to assess the safety and tolerability of the four interventions

    Time frame: 12 hours

07

Study locations

1 site
  • AXIS Clinicals
    Dilworth, Minnesota 56529, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Jul 2021, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2021
First posted
Nov 3, 2021
StartActual
Jul 1, 2021
Primary completionActual
Jul 21, 2021
CompletionActual
Jul 21, 2021
Last update
Nov 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05106400
Lead sponsor
Scilex Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Nov 3, 2021
Start date
Jul 1, 2021
Primary completion
Jul 21, 2021
Completion
Jul 21, 2021
Last update
Nov 3, 2021

Study contacts

Dmitri Lissin, MD
study director · Chief Medical Officer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lidocaine · Lidoderm

Start the discussion